Robert Alonso
Directeur/Membre du Conseil chez MEDESIS PHARMA S.A.
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Jean-Claude Maurel | M | - | 21 ans | |
| Linda P. Dwoskin | F | - |
Ceptaris Therapeutics, Inc.
 Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | 22 ans |
| John G. Geisler | M | - |
Mitochon Pharmaceuticals, Inc.
 Mitochon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mitochon Pharmaceuticals, Inc. operates as a biotech company. It focuses on developing drugs that target the mitochondria for a host of serious diseases. The firm provides products to resolve the over-nutritional phenotype metabolic disorders. The company was founded by Robert Alonso and John G. Geisler in 2014 and is headquartered in Blue Bell, PA. | 10 ans |
| Olivier Connes | M | - | 6 ans | |
| Bernard Connes-Lafforet | M | - | 5 ans | |
| Walt Linscott | M | 63 | 2 ans | |
| Mario Alcaraz | M | - | - | |
| Jean-Marie Cazaledes | M | - | 9 ans | |
| Cédric Navas | M | - | 6 ans | |
| Emmanuel Hebert | M | - | 5 ans | |
| Jean-Philippe Causse | M | - | 3 ans | |
| Solene Guilliot | M | - | 3 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Stephen Tullman | M | 58 |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | 2 ans |
| Kamil Ali-Jackson | F | 65 |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | 2 ans |
| Peter Crooks | M | - |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | - |
| H. Wilkins | M | 62 |
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | 3 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| France | 10 | 62,50% |
| Etats-Unis | 6 | 37,50% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Robert Alonso
- Réseau Personnel
